학술논문

Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses
Document Type
article
Source
Science Translational Medicine. 14(634)
Subject
Medical Microbiology
Biomedical and Clinical Sciences
Immunology
Pneumonia
Emerging Infectious Diseases
Biodefense
Pneumonia & Influenza
Prevention
Biotechnology
Vaccine Related
Lung
Clinical Research
Infectious Diseases
Immunization
3.4 Vaccines
Prevention of disease and conditions
and promotion of well-being
Infection
Good Health and Well Being
Adult
Antibodies
Neutralizing
Antibodies
Viral
COVID-19
COVID-19 Vaccines
Female
Humans
Pregnancy
Pregnancy Complications
Infectious
SARS-CoV-2
Spike Glycoprotein
Coronavirus
Vaccines
Synthetic
mRNA Vaccines
Biological Sciences
Medical and Health Sciences
Medical biotechnology
Biomedical engineering
Language
Abstract
Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that have mutations associated with increased transmission and antibody escape have arisen over the course of the current pandemic. Although the current vaccines have largely been effective against past variants, the number of mutations found on the Omicron (B.1.1.529) spike protein appear to diminish the protection conferred by preexisting immunity. Using vesicular stomatitis virus (VSV) pseudoparticles expressing the spike protein of several SARS-CoV-2 variants, we evaluated the magnitude and breadth of the neutralizing antibody response over time in individuals after infection and in mRNA-vaccinated individuals. We observed that boosting increases the magnitude of the antibody response to wild-type (D614), Beta, Delta, and Omicron variants; however, the Omicron variant was the most resistant to neutralization. We further observed that vaccinated healthy adults had robust and broad antibody responses, whereas responses may have been reduced in vaccinated pregnant women, underscoring the importance of learning how to maximize mRNA vaccine responses in pregnant populations. Findings from this study show substantial heterogeneity in the magnitude and breadth of responses after infection and mRNA vaccination and may support the addition of more conserved viral antigens to existing SARS-CoV-2 vaccines.